Show simple item record

dc.contributor.authorLukambagire, AbdulHamid
dc.contributor.authorMendes, Ângelo
dc.contributor.authorBodenham, Rebecca
dc.contributor.authorMcGiven, John
dc.contributor.authorMkenda, Nestory
dc.contributor.authorMathew, Coletha
dc.contributor.authorRubach, Matthew
dc.contributor.authorSakasaka, Philoteus
dc.contributor.authorShayo, Davis
dc.contributor.authorMaro, Venance
dc.contributor.authorShirima, Gabriel
dc.contributor.authorKasanga, Christopher
dc.contributor.authorKazwala, Rudovick
dc.contributor.authorHalliday, Jo
dc.contributor.authorMmbaga, Blandina
dc.date.accessioned2023-09-25T07:46:33Z
dc.date.available2023-09-25T07:46:33Z
dc.date.issued2021-03-09
dc.identifier.urihttps://doi.org/10.1038/s41598-021-82906-w
dc.identifier.urihttps://dspace.nm-aist.ac.tz/handle/20.500.12479/2058
dc.descriptionThis research article was published in the Scientific Reports volume 11, Article number: 5480, 2021en_US
dc.description.abstractThe control of brucellosis across sub-Saharan Africa is hampered by the lack of standardized testing and the use of tests with poor performance. This study evaluated the performance and costs of serological assays for human brucellosis in a pastoralist community in northern Tanzania. Serum collected from 218 febrile hospital patients was used to evaluate the performance of seven index tests, selected based on international recommendation or current use. We evaluated the Rose Bengal test (RBT) using two protocols, four commercial agglutination tests and a competitive enzyme-linked immunosorbent assay (cELISA). The sensitivity, specificity, positive predictive value, negative predictive value, Youden’s index, diagnostic accuracy, and per-sample cost of each index test were estimated. The diagnostic accuracy estimates ranged from 95.9 to 97.7% for the RBT, 55.0 to 72.0% for the commercial plate tests, and 89.4% for the cELISA. The per-sample cost range was $0.69–$0.79 for the RBT, $1.03–$1.14 for the commercial plate tests, and $2.51 for the cELISA. The widely used commercial plate tests performed poorly and cost more than the RBT. These findings provide evidence for the public health value of discontinuing the use of commercial agglutination tests for human brucellosis in Tanzania.en_US
dc.language.isoenen_US
dc.publisherSpringer Nature Limiteden_US
dc.subjectBacterial infectionen_US
dc.subjectBacteriologyen_US
dc.subjectDiagnosisen_US
dc.subjectEpidemiologyen_US
dc.subjectHealth care economicsen_US
dc.subjectHealth policyen_US
dc.subjectInfectionen_US
dc.subjectInfectious-disease diagnosticsen_US
dc.subjectLaboratory techniques and proceduresen_US
dc.subjectPolicy and public health in microbiologyen_US
dc.subjectPopulation screeningen_US
dc.titlePerformance characteristics and costs of serological tests for brucellosis in a pastoralist community of northern Tanzaniaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record